questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the requirement in the NHS England Commercial Framework for New Medicines for medicines to provide value at-or-below NICE’s cost-effectiveness
heading: Rare Diseases: Drugs